Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
IS07 - Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer
- 16:45 - 17:45
- 1/28/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS07.01 - The Past, Present and Future of Biomarker-Driven Advanced NSCLC
16:45 - 17:15 | Presenter: Benjamin Solomon, Shirish Madhav Gadgeel, Solange Peters
- Abstract
No abstract available for this presentation
-
+
FP14 - Targeted Therapy - Clinically Focused
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Targeted Therapy - Clinically Focused
-
+
FP14.05 - LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).
00:00 - 00:00 | Presenter: Koichi Goto
- Abstract
Loading...
-
+
P39 - Patient Advocacy
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Patient Advocacy
-
+
P39.06 - Surviving Metastatic Non-Small Cell Lung Cancer – Experience and Supportive Care Needs of Patients Receiving Novel Therapies
00:00 - 00:00 | Presenter: Sarah Ellen Heynemann
- Abstract
Loading...
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P76.64 - Alternating Osimertinib and Gefitinib as Second-Line Treatment for EGFR-Mutated NSCLC Harbouring a T790M Resistance Mutation (OSCILLATE)
00:00 - 00:00 | Presenter: Benjamin Solomon
- Abstract
Loading...
-
+
P84 - Targeted Therapy - Clinically Focused - ALK
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P84.09 - Asian Subgroup Analysis of a Phase II Study Evaluating Lorlatinib Efficacy in Previously Treated ALK-Positive Advanced NSCLC
00:00 - 00:00 | Presenter: Ross Soo
- Abstract
Loading...
-
+
ES19 - Patient-Reported Outcomes, Patient Registries and Real-World Evidence: Learning Directly from Patients
- 16:45 - 17:45
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Patient Advocacy
-
+
ES19.03 - Understanding the Feasibility of Patient Reported Outcomes
16:45 - 17:00 | Presenter: Karla Gough
- Abstract
Loading...
-
+
MA11 - Expanding Targetable Genetic Alterations in NSCLC
- 14:15 - 15:15
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Targeted Therapy - Clinically Focused
-
+
MA11.07 - Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
14:35 - 14:40 | Presenter: Byoung Chul Cho
- Abstract
Loading... -
+
MA11.08 - Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC
14:40 - 14:45 | Presenter: Julien Mazieres
- Abstract
Loading... -
+
MA11.09 - Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer
14:45 - 14:50 | Presenter: Daniel SW Tan
- Abstract
Loading...